{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:41:47Z","timestamp":1774413707249,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,8,19]],"date-time":"2007-08-19T00:00:00Z","timestamp":1187481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2007,10,15]]},"DOI":"10.1245\/s10434-007-9539-9","type":"journal-article","created":{"date-parts":[[2007,8,18]],"date-time":"2007-08-18T13:38:48Z","timestamp":1187444328000},"page":"3202-3209","source":"Crossref","is-referenced-by-count":60,"title":["A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study"],"prefix":"10.1245","volume":"14","author":[{"given":"Renuka V.","family":"Iyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Kuvshinoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Kepner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Soehnlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind M.","family":"Javle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,19]]},"reference":[{"key":"9539_CR1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","volume":"33","author":"T Patel","year":"2001","unstructured":"Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353\u20131357","journal-title":"Hepatology"},{"issue":"18","key":"9539_CR2","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","volume":"341","author":"PC Groen de","year":"1999","unstructured":"de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341(18):1368\u201378","journal-title":"N Engl J Med"},{"issue":"2","key":"9539_CR3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2):106\u201330","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"9539_CR4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2007-1007302","volume":"14","author":"JN Vauthey","year":"1994","unstructured":"Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14(2):109\u201314","journal-title":"Semin Liver Dis"},{"issue":"6","key":"9539_CR5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","volume":"54","author":"G Falkson","year":"1984","unstructured":"Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984;54(6):965\u20139","journal-title":"Cancer"},{"issue":"7","key":"9539_CR6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/oxfordjournals.annonc.a058597","volume":"4","author":"BG Taal","year":"1993","unstructured":"Taal BG, Audisio RA, Bleiberg H, et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 1993; 4(7):607\u20139","journal-title":"Ann Oncol"},{"issue":"11","key":"9539_CR7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1984.2.11.1245","volume":"2","author":"JH Harvey","year":"1984","unstructured":"Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2(11):1245\u20138","journal-title":"J Clin Oncol"},{"issue":"7","key":"9539_CR8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0959-8049(97)10166-6","volume":"34","author":"M Hejna","year":"1998","unstructured":"Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998; 34(7):977\u201386","journal-title":"Eur J Cancer"},{"issue":"6","key":"9539_CR9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/oxfordjournals.annonc.a010687","volume":"7","author":"A Polyzos","year":"1996","unstructured":"Polyzos A, Nikou G, Giannopoulos A, et al. Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study. Ann Oncol 1996; 7(6):644\u20135","journal-title":"Ann Oncol"},{"issue":"4","key":"9539_CR10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00000421-200008000-00023","volume":"23","author":"CW Choi","year":"2000","unstructured":"Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23(4):425\u20138","journal-title":"Am J Clin Oncol"},{"key":"9539_CR11","doi-asserted-by":"crossref","unstructured":"Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003; 26(2):124\u20136","DOI":"10.1097\/00000421-200304000-00004"},{"issue":"2","key":"9539_CR12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","volume":"12","author":"M Penz","year":"2001","unstructured":"Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12(2):183\u20136","journal-title":"Ann Oncol"},{"issue":"10","key":"9539_CR13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","volume":"12","author":"JO Gallardo","year":"2001","unstructured":"Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12(10):1403\u20136","journal-title":"Ann Oncol"},{"issue":"2","key":"9539_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","volume":"22","author":"N Tsavaris","year":"2004","unstructured":"Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22(2):193\u20138","journal-title":"Invest New Drugs"},{"issue":"6","key":"9539_CR15","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6):2403\u201313","journal-title":"J Clin Oncol"},{"key":"9539_CR16","unstructured":"Sawada N, Fujimoto-Ouchi K, Ishikawa T, et al: Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002 (abstr 5388)"},{"issue":"2","key":"9539_CR17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2002.20.2.582","volume":"20","author":"RL Schilsky","year":"2002","unstructured":"Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 2002; 20(2):582\u20137","journal-title":"J Clin Oncol"},{"issue":"1","key":"9539_CR18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JCO.2003.04.029","volume":"21","author":"V Hess","year":"2003","unstructured":"Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I\/II trial. J Clin Oncol 2003; 21(1):66\u20138","journal-title":"J Clin Oncol"},{"issue":"20","key":"9539_CR19","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","volume":"19","author":"V Gebbia","year":"2001","unstructured":"Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19(20):4089\u201391","journal-title":"J Clin Oncol"},{"issue":"14","key":"9539_CR20","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","volume":"18","author":"AP Venook","year":"2000","unstructured":"Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18(14):2780\u20137","journal-title":"J Clin Oncol"},{"key":"9539_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. JNCI 1993; 85:365\u2013376","journal-title":"JNCI"},{"key":"9539_CR22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","volume":"35","author":"D Fizsimmons","year":"1999","unstructured":"Fizsimmons D, Johnson CD, George S, et al. Development of a Disease Specific Quality of Life (QoL) Questionnaire Module to Supplement the EORTC Core Cancer QoL Questionnaire, the QLQ-C30 in Patients with Pancreatic Cancer. European J of Cancer 1999; 35:939\u201394","journal-title":"European J of Cancer"},{"issue":"3","key":"9539_CR23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.cct.2004.03.004","volume":"25","author":"JL Kepner","year":"2004","unstructured":"Kepner JL, Chang MN. Samples of exact k-stage group sequential designs for phase II and pilot studies. Controlled Clinical Trials 2004; 25(3):326\u201333","journal-title":"Controlled Clinical Trials"},{"key":"9539_CR24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1201\/9781420035438","volume-title":"Design and Analysis of Quality of Life Studies in Clinical Trials","author":"DL Fairclough","year":"2002","unstructured":"Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. New York: Chapman and Hall\/CRC, 2002, pp 5"},{"issue":"10","key":"9539_CR25","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23(10):2332\u20138","journal-title":"J Clin Oncol"},{"issue":"19","key":"9539_CR26","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2005.05.3579","volume":"24","author":"PA Philip","year":"2006","unstructured":"Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24(19):3069\u201374","journal-title":"J Clin Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-007-9539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-007-9539-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-007-9539-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:26:36Z","timestamp":1572953196000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-007-9539-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,19]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,10,15]]}},"alternative-id":["9539"],"URL":"https:\/\/doi.org\/10.1245\/s10434-007-9539-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,19]]}}}